| Dorothy Estelle Powell, APRN, FNP-BC | |
|
1019 Highway 17 S Ste 121, North Myrtle Beach, SC 29582-3702 | |
| (184) 360-5245 | |
| Not Available |
| Full Name | Dorothy Estelle Powell |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 1019 Highway 17 S Ste 121, North Myrtle Beach, South Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629712989 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 26028 (South Carolina) | Primary |
| Entity Name | Hcr Manorcare Medical Services Of Florida Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386750420 PECOS PAC ID: 2264338532 Enrollment ID: O20110322000718 |
News Archive
NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Switching to tenofovir may stave further kidney and bone impairment in patients with hepatitis B virus-related chronic hepatitis taking adefovir-based therapy, retrospective study findings suggest.
The Environmental Protection Agency (EPA) on Monday "said greenhouse gases are a danger to public health and welfare in a decision that could eventually lead to new emissions regulations," the Wall Street Journal reports (Ball/Forelle/Talley, 12/7). According to the Associated Press/ABC News, the declaration on the opening day of the U.N. Climate Change Conference "signaled the [Obama] administration was prepared to push ahead for significant controls in the U.S. if Congress doesn't act first on its own" (Herbert/Cappiello, 12/7).
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
› Verified 8 days ago
| Entity Name | Signify Health Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750845863 PECOS PAC ID: 2163764424 Enrollment ID: O20191209002986 |
News Archive
NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Switching to tenofovir may stave further kidney and bone impairment in patients with hepatitis B virus-related chronic hepatitis taking adefovir-based therapy, retrospective study findings suggest.
The Environmental Protection Agency (EPA) on Monday "said greenhouse gases are a danger to public health and welfare in a decision that could eventually lead to new emissions regulations," the Wall Street Journal reports (Ball/Forelle/Talley, 12/7). According to the Associated Press/ABC News, the declaration on the opening day of the U.N. Climate Change Conference "signaled the [Obama] administration was prepared to push ahead for significant controls in the U.S. if Congress doesn't act first on its own" (Herbert/Cappiello, 12/7).
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dorothy Estelle Powell, APRN, FNP-BC 761 Flowering Branch Ave, Little River, SC 29566-6604 Ph: (843) 605-2455 | Dorothy Estelle Powell, APRN, FNP-BC 1019 Highway 17 S Ste 121, North Myrtle Beach, SC 29582-3702 Ph: (184) 360-5245 |
News Archive
NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Switching to tenofovir may stave further kidney and bone impairment in patients with hepatitis B virus-related chronic hepatitis taking adefovir-based therapy, retrospective study findings suggest.
The Environmental Protection Agency (EPA) on Monday "said greenhouse gases are a danger to public health and welfare in a decision that could eventually lead to new emissions regulations," the Wall Street Journal reports (Ball/Forelle/Talley, 12/7). According to the Associated Press/ABC News, the declaration on the opening day of the U.N. Climate Change Conference "signaled the [Obama] administration was prepared to push ahead for significant controls in the U.S. if Congress doesn't act first on its own" (Herbert/Cappiello, 12/7).
Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).
› Verified 8 days ago
Roman Koryakin, FNP, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3816 Highway 17 S, North Myrtle Beach, SC 29582 Phone: 843-272-1411 | |
Sandra Lee Payne, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1010 Highway 17 N, North Myrtle Beach, SC 29582 Phone: 843-249-1451 | |
Ms. Stacey Lynn Shaw, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2423 Highway 17 S, North Myrtle Beach, SC 29582 Phone: 843-919-0700 Fax: 843-919-0727 | |
Joann Kay Williams, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1010 Highway 17 N, North Myrtle Beach, SC 29582 Phone: 866-389-2727 | |
Mrs. Tisha Michelle Brown, APRN, FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1010 Highway 17 N, North Myrtle Beach, SC 29582 Phone: 866-389-2727 | |
Tracey Michelle Lewis, APRN, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2021 N Myrtle Point Blvd Ste 102, North Myrtle Beach, SC 29582 Phone: 843-366-3060 Fax: 843-366-3069 | |
Jessica Smith, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1010 Highway 17 N, North Myrtle Beach, SC 29582 Phone: 843-685-0180 |